Geode Capital Management LLC Has $375.26 Million Stock Position in Illumina, Inc. $ILMN

Geode Capital Management LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,869,047 shares of the life sciences company’s stock after buying an additional 130,139 shares during the quarter. Geode Capital Management LLC’s holdings in Illumina were worth $375,260,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after purchasing an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co bought a new stake in Illumina in the 3rd quarter worth about $2,319,000. Caprock Group LLC bought a new stake in Illumina in the 3rd quarter worth about $1,479,000. Capital World Investors grew its position in Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Illumina

In other news, Director Keith A. Meister sold 104,393 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total value of $15,172,478.62. Following the sale, the director owned 3,500,048 shares of the company’s stock, valued at $508,696,976.32. The trade was a 2.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 330,160 shares of company stock worth $48,028,308. Insiders own 2.90% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN opened at $162.96 on Monday. The company’s 50 day moving average is $133.73 and its 200-day moving average is $132.09. Illumina, Inc. has a 12-month low of $78.79 and a 12-month high of $165.37. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The firm has a market cap of $24.66 billion, a P/E ratio of 29.63, a price-to-earnings-growth ratio of 2.70 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the firm posted $0.97 earnings per share. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of recent analyst reports. Robert W. Baird set a $137.00 price objective on shares of Illumina in a research report on Friday, February 6th. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Canaccord Genuity Group lowered their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Barclays lifted their price objective on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Illumina presently has an average rating of “Hold” and an average price target of $137.75.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.